5.30
0.01 (0.19%)
0.01 (0.19%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
Big Cap Pro
Monthly Subscription
for only
|
Small Cap Pro
Monthly Subscription
for only
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Summit Therapeutics Inc | SMMT | NASDAQ | Depository Receipt |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.01 | 0.19% | 5.30 | 20:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.30 | 5.13 | 5.39 | 5.30 | 5.29 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
5.04 | 6.00 | 0.96 | - | - |
Trades | Volume | VWAP | Dollar Volume | Avg Volume |
---|---|---|---|---|
821 | 103,187 | 5.26 | 542,778 | 235,758 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:20 | formt | 238 | 5.30 | USD |
Summit Therapeutics Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
435.67M | 82.20M | 82.20M | 773.17k | - | -0.17 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | 0.00% | - | - |
News Summit Therapeutics
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SMMT Historical
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
Summit Therapeutics Inc is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of medicines for indications for which there inadequate or no therapies. It also conducts clinical programs focused on the genetic disease Cuchenne muscular dystrohy and the infectious disease Clostridium difficile infection. The company has drug development segment. All assets of the company are located in the United Kingdom. |